Asiaticoside alleviated NAFLD by activating Nrf2 and inhibiting the NF-κB pathway
- PMID: 39667137
- DOI: 10.1016/j.phymed.2024.156317
Asiaticoside alleviated NAFLD by activating Nrf2 and inhibiting the NF-κB pathway
Abstract
Background: Nonalcoholic fatty liver disease (NAFLD) is a globally prevalent clinical problem of chronic liver disorder whose main pathogenic mechanisms are hepatic lipid accumulation, oxidative stress, and inflammatory reactions. Asiaticoside (Asi) is a compound derived from Centella asiatica, possesses antioxidant, antiphlogistic, antifibrotic, as well as wound healing properties.
Purpose: The aim of this study was to investigate the effects of Asi on NAFLD and its potential mechanisms.
Study design: Two versions of experimental models were constructed using free fatty acids (FFAs)-stimulated HepG2 cells along with high-fat diet (HFD)-incited NAFLD in mice.
Methods: The pivotal action of Nrf2 was then explored using Ml-385 or Nrf2-/- mice.
Results: The results indicated that Asi activated the Nrf2 to alleviate oxidative stress, inhibited the NF-κB to reduce the inflammatory response, and notably decreased lipid droplets and alleviated steatosis.
Conclusion: In conclusion, Asi demonstrates a potential to activate Nrf2 as well as inhibit the NF-κB pathway, there alleviate NAFLD.
Keywords: Asiaticoside; NAFLD; NF-κB; Nrf2.
Copyright © 2024. Published by Elsevier GmbH.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Bioinformatics based exploration of the anti-NAFLD mechanism of Wang's empirical formula via TLR4/NF-κB/COX2 pathway.Mol Med. 2024 Dec 27;30(1):278. doi: 10.1186/s10020-024-01022-3. Mol Med. 2024. PMID: 39730994 Free PMC article.
-
Helenalin from Centipeda minima ameliorates acute hepatic injury by protecting mitochondria function, activating Nrf2 pathway and inhibiting NF-κB activation.Biomed Pharmacother. 2019 Nov;119:109435. doi: 10.1016/j.biopha.2019.109435. Epub 2019 Sep 11. Biomed Pharmacother. 2019. Retraction in: Biomed Pharmacother. 2024 Dec;181:117697. doi: 10.1016/j.biopha.2024.117697. PMID: 31520915 Retracted.
-
Abscisic acid improves non-alcoholic fatty liver disease in mice through the AMPK/NRF2/KEAP1 signaling axis.Biochem Biophys Res Commun. 2025 Feb 2;747:151291. doi: 10.1016/j.bbrc.2025.151291. Epub 2025 Jan 6. Biochem Biophys Res Commun. 2025. PMID: 39793400
-
Nonalcoholic Fatty Liver Disease and Staging of Hepatic Fibrosis.Adv Exp Med Biol. 2024;1460:539-574. doi: 10.1007/978-3-031-63657-8_18. Adv Exp Med Biol. 2024. PMID: 39287864 Review.
-
Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease.World J Gastroenterol. 2014 Oct 21;20(39):14205-18. doi: 10.3748/wjg.v20.i39.14205. World J Gastroenterol. 2014. PMID: 25339807 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical